Hepatitis A is the most common form of viral hepatitis in terms of global new infections each year — yet it is also the most benign and the most readily preventable. Unlike hepatitis B and C, hepatitis A never causes chronic infection: every person who contracts it either recovers fully within two to three months (the vast majority) or, in a small minority, develops a more prolonged illness that still ultimately resolves without lasting liver damage. Hepatitis A does not cause cirrhosis. It does not cause liver cancer. And it is prevented with extraordinary effectiveness by a vaccine that provides protective immunity in over ninety-five percent of recipients after two doses. Understanding hepatitis A — how it spreads, what symptoms it causes, who is at highest risk, and when to seek medical attention — equips adults and families to protect themselves with confidence and to recognise the condition promptly if it does occur.
What Causes Hepatitis A
Hepatitis A is caused by the hepatitis A virus (HAV), a non-enveloped positive-sense single-stranded RNA virus belonging to the Picornaviridae family. HAV is transmitted exclusively via the faecal-oral route — it is shed in the faeces of infected individuals and acquired when contaminated material enters another person’s mouth. This can occur through: Contaminated food and water: The most common transmission route globally. Foods most frequently implicated include raw or undercooked shellfish (particularly bivalves such as oysters, clams, and mussels, which filter large volumes of water and concentrate viral particles), raw produce, salads, and sandwiches handled by an infected food preparer. Water contamination is a major route in regions with inadequate sanitation infrastructure. Close person-to-person contact: Household contacts of infected individuals, particularly in settings with young children in nappies, face significant transmission risk from faecal contamination of surfaces and inadequate hand hygiene. Sexual transmission through anal-oral contact (rimming) is documented as a transmission route in men who have sex with men. Travel to endemic regions: HAV is endemic in regions with limited access to clean water and sanitation — sub-Saharan Africa, South and Central Asia, Central and South America, the Middle East, and parts of Eastern Europe. Unvaccinated travellers from low-prevalence countries visiting these regions face substantially elevated infection risk. Institutional settings: Outbreaks have been documented in childcare centres, schools, and among people experiencing homelessness. HAV is remarkable for its stability outside the human body — it survives for months in water, withstands acid (enabling it to survive passage through the stomach), and requires sustained heating (above eighty-five degrees Celsius for one minute) for inactivation, which is why inadequate cooking of shellfish is a persistent transmission risk.
Symptoms of Hepatitis A: What to Expect
The incubation period for hepatitis A — the time between exposure and symptom onset — ranges from fifteen to fifty days, with an average of approximately twenty-eight days. This prolonged incubation period means that infected individuals often cannot identify when or where they were exposed. The clinical course of hepatitis A has two phases: Prodromal (pre-icteric) phase lasting one to two weeks: onset is typically abrupt, with fatigue, malaise, loss of appetite, nausea, vomiting, low-grade fever, headache, myalgia, and right upper quadrant discomfort. These symptoms are non-specific and easily confused with influenza or gastroenteritis at this stage. Icteric (jaundice) phase lasting two to six weeks in typical cases: as the systemic symptoms begin to improve, jaundice develops in approximately seventy percent of symptomatic adults — yellowing of the sclera (whites of the eyes) and skin, dark urine (described as tea-coloured), pale or clay-coloured stools (reflecting reduced bile excretion), and pruritus (itching). ALT and AST levels peak during this phase — typically ten to forty times the upper limit of normal, reflecting extensive hepatocyte damage. A clinically important feature of hepatitis A is that children under the age of six years are usually asymptomatic (approximately seventy percent have no symptoms at all), while older children and adults have progressively more symptomatic disease. This epidemiological asymmetry means that young children can be important silent transmission vectors in household and institutional settings. The majority of healthy adults recover completely within two months. A minority (approximately ten to fifteen percent) experience a relapsing course — symptom resolution followed by recurrence — over three to six months, before ultimately recovering fully. Fulminant hepatic failure occurs in less than one percent of cases overall but is more frequent in older adults and those with pre-existing liver disease including chronic hepatitis B or C, alcohol-related liver disease, or MASLD.
Who Is at Highest Risk
While anyone can contract hepatitis A, certain groups face substantially elevated risk and should be prioritised for vaccination: Travellers to endemic regions: Travel to areas with intermediate or high HAV endemicity — including most of sub-Saharan Africa, South Asia, Southeast Asia, Central and South America, and parts of the Middle East and Eastern Europe — significantly increases infection risk for unvaccinated travellers. Vaccination should be completed at least two weeks before travel, with the first dose providing approximately ninety-five percent protection within four weeks. Men who have sex with men (MSM): Multiple HAV outbreaks have occurred in MSM networks in Europe and North America, where sexual transmission through anal-oral contact is the predominant route. Vaccination is strongly recommended for MSM regardless of travel plans. People who inject drugs: Sharing contaminated injecting equipment and poor sanitation conditions elevate HAV risk among people who inject drugs. People with chronic liver disease: Those with pre-existing liver conditions — including chronic HBV, chronic HCV, MASLD, and alcoholic liver disease — face much higher risk of fulminant hepatic failure if they contract HAV, making vaccination particularly important in this group. Household contacts of HAV-positive individuals: Close household contacts (particularly those sharing food preparation or caring for young children) of a person with confirmed HAV infection require post-exposure prophylaxis — either HAV vaccination (if within fourteen days of exposure) or hepatitis A immunoglobulin for those who cannot receive the vaccine. People living in or travelling to areas with outbreaks: Healthcare authorities issue outbreak advisories when community HAV transmission is identified — vaccination is the appropriate response for unvaccinated individuals in affected areas.
Hepatitis A Vaccine: Prevention That Works
The hepatitis A vaccine is one of the most effective vaccines in the routine immunisation schedule — it provides protection in over ninety-five percent of recipients and confers long-lasting immunity estimated at twenty years or more after completing the two-dose primary course. The vaccination schedule consists of two doses given six to twelve months apart. A single dose provides protection within two to four weeks in the large majority of recipients, making it appropriate for pre-travel vaccination even with limited lead time. The vaccine is safe for adults and children over one year of age. Side effects are mild and transient — soreness at the injection site, low-grade fever, and headache for one to two days following injection. In the UK, the hepatitis A vaccine is available free on the NHS for at-risk groups (including household contacts of confirmed cases, people with chronic liver disease, MSM, people who inject drugs, and some occupational groups including sewage workers and laboratory workers handling HAV). It is available as a travel vaccine through GP practices and travel health clinics for travellers to endemic regions. A combined hepatitis A and B vaccine (Twinrix) is also available and is efficient for individuals who require protection against both viruses. Once the two-dose primary course is completed, booster doses are not required for most immunocompetent individuals — a single booster at five to ten years is considered in travellers making repeated visits to endemic regions and in immunocompromised individuals.
Diagnosis and Management
Hepatitis A is diagnosed by detecting anti-HAV IgM antibodies in blood — a test that becomes positive at or shortly after symptom onset and remains positive for three to six months. The presence of anti-HAV IgG without IgM indicates past infection or vaccination and confirmed immunity. Liver function tests will show elevated ALT and AST (often ten to forty times normal) and elevated bilirubin in icteric cases. There is no specific antiviral treatment for hepatitis A — management is supportive. The key principles of supportive management include: rest during the acute illness phase (though bed rest is not required); adequate hydration (particularly important if vomiting is significant); avoidance of alcohol (which adds additional hepatic burden during active liver inflammation); avoidance of paracetamol and other hepatically metabolised medications where possible; and avoidance of fatty foods if nausea and biliary dysfunction are prominent. Hospital admission is required for: significant dehydration unable to be managed at home; severe coagulopathy (prolonged prothrombin time indicating hepatic synthetic failure); encephalopathy (confusion or altered consciousness indicating hepatic failure); and jaundice with a very elevated bilirubin or prothrombin time suggesting progression toward fulminant hepatic failure. Most patients can be managed at home with primary care monitoring of liver blood tests every one to two weeks until resolution. Return to work and normal activity can typically occur once the patient feels well enough and jaundice has resolved — there is no fixed exclusion period, but food handlers and healthcare workers should be excluded from work while symptomatic and for one week after jaundice onset.
Frequently Asked Questions
How long does hepatitis A last?
Most people recover fully within two months of symptom onset. Jaundice typically resolves within four weeks, and fatigue may persist for up to three months in some cases. Approximately ten to fifteen percent of patients have a relapsing course lasting up to six months — with a period of apparent recovery followed by return of symptoms — but these patients also recover fully without chronic liver disease. There are no long-term liver consequences of hepatitis A in immunocompetent individuals. Those with pre-existing liver conditions recover more slowly and face higher risk of complications, but the large majority still recover without lasting additional liver damage.
Am I immune to hepatitis A after having it?
Yes — HAV infection confers lifelong immunity. Once you have had hepatitis A, you cannot be reinfected with it. If you are uncertain whether you have had hepatitis A in the past, a blood test for anti-HAV IgG can confirm immune status. If you test negative (not immune) and have not been vaccinated, vaccination is recommended if you have any of the risk factors described in this guide. GGT levels may remain mildly elevated for several months after acute hepatitis A resolution — this is normal and does not indicate ongoing liver disease.
Sources: WHO — Hepatitis A Fact Sheet · NIDDK — Hepatitis A · CDC — Hepatitis A Information
Hepatitis A in Pregnancy
Hepatitis A during pregnancy does not cause congenital infection or fetal abnormalities — HAV does not cross the placenta and does not affect the developing fetus. However, pregnant women who contract hepatitis A face a higher risk of complications including premature labour (particularly in the third trimester), preterm birth, and — in severe hepatitis A cases — greater risk of fulminant hepatic failure compared with non-pregnant adults. The hepatitis A vaccine is safe in pregnancy — it is an inactivated vaccine with no live viral components — and is recommended for pregnant women who are unvaccinated and will be travelling to endemic regions or who have had significant exposure to a confirmed case. Post-exposure prophylaxis with hepatitis A immunoglobulin can be given alongside vaccination within fourteen days of exposure for close contacts of confirmed cases, including pregnant women. Breastfeeding is not a contraindication to HAV vaccination or to continued breastfeeding after acute hepatitis A, provided the mother is not severely unwell. Mothers with acute hepatitis A should practice meticulous hand hygiene during nappy changes and food preparation to protect their infants, who may be vulnerable to infection if not yet old enough for vaccination.
Hepatitis A Outbreaks: What They Mean for Public Health
Community outbreaks of hepatitis A require rapid public health response because of HAV’s extended incubation period — cases may continue to emerge for up to fifty days after the initial exposure event, meaning that outbreak control requires identifying the source and implementing interventions before all exposed individuals have developed symptoms. When a food vehicle is identified (a contaminated food product distributed to multiple consumers), the public health response includes: product recall and notification of retailers and consumers; contact tracing and post-exposure prophylaxis (vaccination or immunoglobulin) for exposed individuals; investigation of the food supply chain to identify the contamination source. When person-to-person transmission is occurring in a community setting (childcare centre, school, household cluster), the response includes: exclusion of symptomatic cases from the setting until one week after jaundice onset; vaccination of close contacts within fourteen days of exposure; enhanced hand hygiene education and environmental cleaning protocols. The UK Health Security Agency (UKHSA) monitors hepatitis A incidence and issues alerts for confirmed outbreaks — these are publicly available and relevant for GPs and public health practitioners identifying potential linked cases. For travellers returning from endemic regions with acute hepatitis symptoms — fatigue, jaundice, nausea, dark urine — hepatitis A should be in the differential diagnosis regardless of vaccination history, as breakthrough infections (while rare) can occur. ALT and bilirubin testing and anti-HAV IgM serology will confirm or exclude the diagnosis.
Food Safety to Reduce Hepatitis A Risk
Beyond vaccination, food safety practices significantly reduce hepatitis A transmission risk — particularly important for unvaccinated individuals in endemic regions and for food handlers in any setting: Thorough cooking of shellfish: Oysters, clams, mussels, and other bivalves should be cooked to an internal temperature of ninety degrees Celsius or above — steaming until shells open for at least ninety seconds achieves this. Raw oysters from any source carry HAV risk if the source water was contaminated. Hand hygiene: Thorough handwashing with soap and water for at least twenty seconds after toilet use, after changing nappies, and before food preparation is the single most important individual behaviour for preventing faecal-oral transmission. Alcohol-based hand sanitisers are less effective against HAV than soap and water because HAV’s non-enveloped structure makes it relatively resistant to alcohol. Safe water in endemic regions: Drinking only bottled or boiled water, avoiding ice made from tap water, and using safe water for brushing teeth reduces HAV risk in areas where water quality is uncertain. Food handler hygiene in foodservice settings: Exclusion of symptomatic food handlers from work, mandatory glove use during food preparation, and regular surface sanitation with appropriate disinfectants (bleach-based for HAV inactivation) prevent workplace transmission to customers and colleagues. The combination of vaccination for at-risk groups and food safety practices for everyone provides a robust dual-layer protection strategy against hepatitis A that has driven the progressive decline in hepatitis A incidence in high-income countries over recent decades.
Hepatitis A vs Other Forms of Hepatitis: Key Differences
Understanding how hepatitis A differs from hepatitis B and C helps patients interpret their diagnosis and understand why treatment approaches vary so substantially between these related conditions: Chronicity: Hepatitis A never causes chronic infection — it always resolves completely. Hepatitis B becomes chronic in five to ten percent of adult-acquired cases. Hepatitis C becomes chronic in approximately seventy-five percent of cases. Transmission: Hepatitis A spreads faecal-orally (contaminated food, water, contact). Hepatitis B and C spread through blood and body fluids — hepatitis B also sexually and perinatally. Vaccine availability: Both hepatitis A and hepatitis B have safe, highly effective vaccines. There is currently no licensed hepatitis C vaccine. Treatment: Hepatitis A has no specific treatment — management is supportive. Hepatitis C can now be cured with direct-acting antivirals. Hepatitis B can be suppressed but not currently cured with available antivirals. Liver cancer risk: Hepatitis A carries no liver cancer risk. Chronic hepatitis B and C are major risk factors for hepatocellular carcinoma, particularly in patients who develop cirrhosis. Severity of acute illness: Hepatitis A causes clinically similar acute illness to hepatitis B — jaundice, fatigue, nausea — but the long-term prognosis of hepatitis A is far better. The practical implication for patients is that a diagnosis of acute hepatitis A — while unpleasant and temporarily debilitating — is fundamentally a benign condition with an excellent prognosis, whereas a diagnosis of chronic hepatitis B or C requires active management, treatment consideration, and long-term monitoring. Anyone with acute hepatitis symptoms should have viral serology (anti-HAV IgM, HBsAg, anti-HCV) checked alongside liver function tests to identify the specific causative virus, as the management implications differ substantially between these diagnoses. A FibroScan is not typically needed in acute hepatitis A but may be indicated if the patient has pre-existing liver disease that was suspected to be present before the acute hepatitis episode.
Recovery and Return to Normal Life
Most adults with hepatitis A find the acute illness more debilitating than they anticipated — the combination of fatigue, nausea, and jaundice creates a period of significant functional limitation that can last four to eight weeks. Managing expectations and practical aspects of recovery helps patients navigate this period more effectively. Fatigue management: Rest is important during the acute phase, but enforced bed rest is not required and light activity as tolerated is acceptable. Energy levels typically recover gradually over four to eight weeks — planning for a phased return to work and normal activities rather than an abrupt return when jaundice resolves is more realistic for most patients. Dietary adjustments: Many patients find that high-fat and high-protein meals are poorly tolerated during acute hepatitis A because of reduced bile production and appetite suppression. Small, frequent meals, emphasis on easily digested carbohydrates, and adequate hydration are generally better tolerated. As recovery progresses and jaundice resolves, normal diet can be resumed. Alcohol: Alcohol should be avoided for at least three months after hepatitis A resolution — adding an additional hepatic burden to a liver still in recovery extends convalescence and may prolong abnormal liver enzyme levels. Medications: Paracetamol should be minimised and NSAIDs avoided during active hepatitis A. Regular review of all medications with the prescribing doctor is appropriate, as hepatic metabolism of many drugs is impaired during active liver inflammation. Monitoring: Follow-up liver function tests every two to four weeks confirm the expected trajectory of improvement. Persistently elevated or rising ALT after six weeks warrants review to exclude complications — fulminant hepatic failure, relapsing hepatitis A, or an alternative cause of hepatitis that was not initially identified. Complete recovery from hepatitis A, confirmed by normalised liver function tests and resolved symptoms, generally occurs within two to three months in healthy adults — an outcome that should be communicated early to patients to provide reassurance during the acute phase of what can feel like a severe and prolonged illness.
The story of hepatitis A is, ultimately, one of the clearest public health success stories in modern medicine. A disease that once caused widespread epidemics — contaminating water supplies, spreading through food chains, debilitating communities — is now entirely preventable with two doses of a vaccine that has been safely administered to hundreds of millions of people worldwide. In high-income countries with universal clean water access, strong food safety regulation, and high vaccination coverage in at-risk groups, hepatitis A incidence has declined dramatically over the past three decades. The remaining cases are largely preventable through targeted vaccination of high-risk groups, prompt post-exposure prophylaxis for contacts of confirmed cases, and maintained food safety standards. For individual patients, the practical message is simple: if you are unvaccinated and have any of the risk factors described in this guide — planned travel to an endemic region, sexual practices involving anal-oral contact, close contact with a case, or pre-existing liver disease — vaccination is the single most effective protective action available, and the window for pre-travel vaccination can be as short as two weeks before departure. The GGT and liver health guide and the ALT and AST guide in this series provide further context for anyone interpreting liver blood test results in the context of hepatitis A recovery.
I got hepatitis A after eating oysters at a restaurant last summer. The fatigue was the worst part — I was off work for six weeks and still felt exhausted for two months after the jaundice cleared. Nobody told me that the relapsing form could happen — I thought I was getting better, then the symptoms came back. This article explains exactly what I went through. It would have been incredibly reassuring to read at the time.
Thank you Rachel — the relapsing course of hepatitis A is genuinely underappreciated and can be very distressing for patients who believe they have recovered, only to see symptoms return. The relapsing pattern affects approximately ten to fifteen percent of patients and can extend the overall illness duration to three to six months — but it is important to know that every case of relapsing hepatitis A ultimately resolves completely, and the relapsing course does not indicate a worse long-term prognosis or any risk of chronic liver disease. If you haven’t had your liver function tests rechecked since recovery, it would be worthwhile confirming that ALT has normalised — not because abnormalities are expected at this stage, but because documented normalisation gives you a baseline for any future testing.
I’m travelling to India next month and hadn’t thought about hepatitis A vaccination. I’ve had the hepatitis B vaccine from years ago but never hepatitis A. This article explains clearly that a single dose gives protection within two to four weeks — I’ve booked the travel clinic for next week to get the first dose before departure. Thank you for making the timeline and what the vaccine covers so clear.